Targeting inflammation in cancer prevention and therapy

Cancer Prevention Research

Volumn 9, Issue 12, 2016, Pages 895-905

  Todoric, Jelena ^a,b   Antonucci, Laura ^a   Karin, Michael ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTIINFLAMMATORY AGENT; APRICOXIB; CANCER VACCINE; CARFILZOMIB; CELECOXIB; CIGARETTE SMOKE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; DICLOFENAC; ETORICOXIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; LUMIRACOXIB; METFORMIN; MONOCLONAL ANTIBODY; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; ROFECOXIB; STAT3 PROTEIN; UNINDEXED DRUG; VALDECOXIB;

ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CELL POLARITY; CORTICOSTEROID THERAPY; DIET; EXERCISE; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MEDIATOR; NEOPLASM; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ALCOHOLISM; COMPLICATION; METABOLISM; MICROFLORA;

ALCOHOLISM; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MICROBIOTA; NEOPLASMS; OBESITY; RISK FACTORS; TOBACCO SMOKING;

EID: 85008391748     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0209     Document Type: Review

References (148)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
2. Schmidt A, Weber OF. In memoriam of Rudolf Virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol 2006;13:1-15.
3. Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med 2010;268:15-24.
4. Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration. Nature 2016;529:307-15.
5. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65.
6. Shaked H, Hofseth LJ, Chumanevich A, Chumanevich AA, Wang J, Wang Y, et al. Chronic epithelial NF-kappaB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci USA 2012;109:14007-12.
7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
9. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491:254-8.
10. Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 2014;41:1052-63.
11. Spratt JS. The primary and secondary prevention of cancer. J Surg Oncol 1981;18:219-30.
12. Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol 2013;10:625-42.
13. World Health Organization. Obesity and overweight. Geneva, Swirzerland: WHO Media Centre; 2015. Available from: http://who. int/mediacentre/factsheets/fs311/en/.
14. ArnoldM, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015;16:36-46.
15. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-7.
16. Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the flame. Cell Metab 2016;23:48-62.
17. McNelis JC, Olefsky JM. Macrophages, immunity, andmetabolic disease. Immunity 2014;41:36-48.
18. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.
19. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010;17: 286-97.
20. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
21. Kew MC. Obesity as a cause of hepatocellular carcinoma. Ann Hepatol 2015;14:299-303.
22. Pendyala S, Neff LM, Suarez-Farinas M, Holt PR. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 2011;93:234-42.
23. Bai Y, Sun Q. Macrophage recruitment in obese adipose tissue. Obes Rev 2015;16:127-36.
24. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10:653-62.
25. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadl A, et al. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 2006;49: 2109-19.
26. Sears DD, Miles PD, Chapman J, Ofrecio JM, Almazan F, Thapar D, et al. 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009;4:e7250.
27. Guidelines JDRCD March 29, 2007. Available from: https://www. joslin. org/docs/Nutrition-Guideline-Graded. pdf.
28. Ampuero J, Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: role of statins and metformin. World J Hepatol 2015;7:1105-11.
29. HashibeM, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18: 541-50.
30. Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis 2012;16:839-50.
31. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, et al. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58, 515 women with breast cancer and 95, 067 women without the disease. Br J Cancer 2002;87:1234-45.
32. Sheron N, Hawkey C, Gilmore I. Projections of alcohol deaths-a wake-up call. Lancet 2011;377:1297-9.
33. Crawford JM. Histologic findings in alcoholic liver disease. Clin Liver Dis 2012;16:699-716.
34. Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis 2015;35:146-56.
35. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-76.
36. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011;19:429-31.
37. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014;26:331-43.
38. European Association for the Study of L. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399-420.
39. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146:1513-24.
40. Watanabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sutterwala FS, et al. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2009;296:G1248-57.
41. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008; 42:349-61.
42. Tsuruya A, Kuwahara A, Saito Y, Yamaguchi H, Tsubo T, Suga S, et al. Ecophysiological consequences of alcoholism on human gut microbiota: implications for ethanol-related pathogenesis of colon cancer. Sci Rep 2016;6:27923.
43. Heckley GA, Jarl J, Asamoah BO, U GG. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 2011;11:446.
44. Lang MB, Segersvard R, Grundsten M, Segerdahl M, Arnelo U, Permert J, et al. Management of alcohol use disorders in patients with chronic pancreatitis. JOP 2012;13:654-9.
45. Duell EJ. Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog 2012;51:40-52.
46. Gu H, Fortunato F, Bergmann F, Buchler MW, Whitcomb DC, Werner J. Alcohol exacerbates LPS-induced fibrosis in subclinical acute pancreatitis. Am J Pathol 2013;183:1508-17.
47. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 1997;155:1770-6.
48. Kode A, Yang SR, Rahman I. Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cells and in a variety of transformed alveolar epithelial cells. Respir Res 2006;7:132.
49. Pace E, Ferraro M, Siena L, Melis M, Montalbano AM, Johnson M, et al. Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. Immunology 2008;124:401-11.
50. Lee J, Taneja V, Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 2012;91:142-9.
51. Reynolds PR, Kasteler SD, Schmitt RE, Hoidal JR. Receptor for advanced glycation end-products signals through Ras during tobacco smokeinduced pulmonary inflammation. Am J Respir Cell Mol Biol 2011;45: 411-8.
52. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49: 4682-9.
53. Walters MJ, Paul-Clark MJ, McMaster SK, Ito K, Adcock IM, Mitchell JA. Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol Pharmacol 2005;68: 1343-53.
54. Takahashi H, Ogata H, Nishigaki R, Broide DH, KarinM. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta-and JNK1-dependent inflammation. Cancer Cell 2010;17:89-97.
55. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
56. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-16.
57. Moresco EM, LaVine D, Beutler B. Toll-like receptors. Curr Biol 2011;21: R488-93.
58. Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 2012;209:1671-87.
59. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869-81.
60. Di Caro G, Marchesi F, Laghi L, Grizzi F. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 2013;17:1088-95.
61. Hu B, Elinav E, Huber S, Strowig T, Hao L, Hafemann A, et al. Microbiotainduced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc Natl Acad Sci USA 2013;110:9862-7.
62. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-3.
63. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014;15:317-28.
64. Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol 2016;30: 119-31.
65. FAO/WHO. Report of a Joint FAO/WHO expert consultation on evaluation of health, and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. C-ordoba, Spain: Food and Agriculture Organization of the United Nations, World Health Organization; 2001.
66. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007;137:830S-7S.
67. Kuo SM. The interplay between fiber and the intestinal microbiome in the inflammatory response. Adv Nutr 2013;4:16-28.
68. Idorn M, Hojman P. Exercise-dependent regulation of NK cells in cancer protection. Trends Mol Med 2016;22:565-77.
69. Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical activity and cancer outcomes: a precision medicine approach. Clin Cancer Res 2016;22:4766-75.
70. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83.
71. Pedersen L, IdornM, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, et al. Voluntary running suppresses tumor growth through epinephrineand IL-6-dependent NK cell mobilization and redistribution. Cell Metab 2016;23:554-62.
72. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41.
73. Guo Y, Liu Y, Zhang C, Su ZY, Li W, Huang MT, et al. The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane-and dextran sulfate sodium-treated CF-1 mice. Carcinogenesis 2016;37:616-24.
74. Schror K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 2011;25:473-84.
75. Allaj V, Guo C, Nie D. Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci 2013;3:8.
76. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010;62:233-44.
77. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7.
78. Ranjbar MM, Assadolahi V, Yazdani M, Nikaein D, Rashidieh B. Virtual dual inhibition of COX-2/5-LOX enzymes based on binding properties of alpha-amyrins, the anti-inflammatory compound as a promising anticancer drug. EXCLI J 2016;15:238-45.
79. McGettigan P, Henry D. Cardiovascular risk with non-steroidal antiinflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098.
80. GroschS, MaierTJ, SchiffmannS, GeisslingerG. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-47.
81. Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009;1:29-43.
82. Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004;10:1633-44.
83. WitschiH, Espiritu I, Ly M, UyeminamiD. The chemopreventive effects of orally administered dexamethasone in Strain A/Jmice following cessation of smoke exposure. Inhal Toxicol 2005;17:119-22.
84. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142-52.
85. Jian ZH, Huang JY, Lin FC, Nfor ON, Jhang KM, Ku WY, et al. The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma. BMC Pulm Med 2015;15:154.
86. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
87. JainMK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
88. Massey RU. Reflections from the Dean's office. Conn Med 1976;40:212.
89. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109: II18-26.
90. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013;31:1514-21.
91. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. NEngl JMed 2005;352:2184-92.
92. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:8606-12.
93. Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of antiinflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev 2014;40:68-77.
94. Sehdev A, O'Neil BH. The role of aspirin, vitamin D, exercise, diet, statins, andmetformin in the prevention and treatment of colorectal cancer. Curr Treat Options Oncol 2015;16:43.
95. Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF. Metformin and cancer therapy. Curr Opin Oncol 2012;24:103-8.
96. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
97. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11:762-74.
98. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol 2013;14:986-95.
99. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86.
100. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumormicroenvironment. Cancers (Basel) 2014;6:1670-90.
101. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
102. Karnevi E, Andersson R, Rosendahl AH. Tumour-educated macrophages display amixed polarisation and enhance pancreatic cancer cell invasion. Immunol Cell Biol 2014;92:543-52.
103. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
104. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
105. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015;212:435-45.
106. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 2013;19:3404-15.
107. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-34.
108. Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014; 30:24-31.
109. Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 2015;3:136-48.
110. Olsson A, Nakhle J, Sundstedt A, Plas P, Bauchet AL, Pierron V, et al. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. J Immunother Cancer 2015;3:53.
111. Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages fromM2toM1in ApcMin/\+mouse polyps. Carcinogenesis 2011;32:1333-9.
112. Nagai T, TanakaM, Tsuneyoshi Y, Xu B, Michie SA, Hasui K, et al. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 2009;58:1577-86.
113. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. AnnN Y Acad Sci 2006;1091:151-69.
114. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.
115. Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011;20:1263-75.
116. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014;26:54-74.
117. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011;208:1359-66.
118. KortylewskiM, Xin H, Kujawski M, LeeH, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23.
119. Fagard R, Metelev V, Souissi I, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT 2013;2:e22882.
120. Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Discov 2012;11:103-4.
121. Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2012;8:319-31.
122. Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer 2015;62:1717-24.
123. Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G, et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013;18:819-20.
124. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008;104: 733-44.
125. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, et al. NF-kappaB restricts inflammasome activation via elimination of damaged mitochondria. Cell 2016;164:896-910.
126. Hsu LC, Enzler T, Seita J, Timmer AM, Lee CY, Lai TY, et al. IL-1beta-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKbeta. Nat Immunol 2011;12:144-50.
127. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factorkappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293-302.
128. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlationwith down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 2003;63:4375-83.
129. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270:24995-5000.
130. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res 2012;159:477-86.
131. Ahn DW, Seo JK, Lee SH, Hwang JH, Lee JK, Ryu JK, et al. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Pancreas 2012;41:1048-57.
132. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
133. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 2016;16:407-20.
134. Guo W, Sun Y, Liu W, Wu X, Guo L, Cai P, et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy 2014;10:972-85.
135. Qiao Y, Wang P, Qi J, Zhang L, Gao C. TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBS Lett 2012; 586:1022-6.
136. Nunes T, de Souza HS. Inflammasome in intestinal inflammation and cancer. Mediators Inflamm 2013;2013:654963.
137. Antonucci L, Fagman JB, Kim JY, Todoric J, Gukovsky I, Mackey M, et al. Basal autophagy maintains pancreatic acinar cellhomeostasis and protein synthesis and prevents ER stress. Proc Natl Acad Sci USA 2015;112: E6166-74.
138. Li N, Wu X, Holzer RG, Lee JH, Todoric J, Park EJ, et al. Loss of acinar cell IKKalpha triggers spontaneous pancreatitis in mice. J Clin Invest 2013;123:2231-43.
139. Aghajan M, Li N, Karin M. Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. J Gastroenterol Hepatol 27 Suppl 2012;2:10-4.
140. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
141. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 2015;12:584-96.
142. Wang K, Karin M. The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol 2015;33:S87-90.
143. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015;21:719-29.
144. Bertoletti A, Gehring AJ. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog 2013;9:e1003784.
145. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-59.
146. Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 2015;7:1030-40.
147. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68.
148. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24 Suppl 1:S1-15.